Last Updated: 18 Oct 2024
##
Executive Summary
Amicus Therapeutics Inc. (FOLD) is a biotechnology company focused on developing and delivering drugs for people living with rare metabolic diseases. The company's latest stock price is $11.97, with a market capitalization of $3.55 billion. Amicus Therapeutics has a strong pipeline of drugs in development, including several potential blockbuster drugs. The company is also well-positioned to benefit from the growing demand for rare disease treatments.
##
Company Overview
Amicus Therapeutics was founded in 1992 and is headquartered in Philadelphia, Pennsylvania. The company has a workforce of approximately 600 employees and operates in over 30 countries. Amicus Therapeutics' primary focus is on developing and delivering drugs for people living with rare metabolic diseases. The company's portfolio of drugs includes treatments for Fabry disease, Pompe disease, and Gaucher disease.
##
Fundamental Analysis
Amicus Therapeutics has a strong financial profile. The company is profitable and has a growing revenue stream. In 2023, Amicus Therapeutics reported revenue of $455.7 million, up 34% year-over-year. The company's net income was $16.7 million, up from a loss of $20.1 million in 2022. Amicus Therapeutics has a strong balance sheet with $500 million in cash and equivalents. The company also has a low level of debt.
##
Technical Analysis
Amicus Therapeutics' stock price has been in a downtrend since early 2023. The stock price fell from a high of $14.57 in January 2023 to a low of $9.02 in June 2023. The stock price has since rebounded and is currently trading at $11.97. The stock's technical indicators are mixed. The relative strength index (RSI) is below 50, indicating that the stock is oversold. The moving average convergence divergence (MACD) is also below zero, indicating that the stock is in a downtrend.
##
Short Term Outlook
The short-term outlook for Amicus Therapeutics is mixed. The stock price is currently trading below its 50-day and 200-day moving averages. The stock's technical indicators are also mixed. However, the company has a strong pipeline of drugs in development and is well-positioned to benefit from the growing demand for rare disease treatments.
##
Long Term Outlook
The long-term outlook for Amicus Therapeutics is positive. The company has a strong pipeline of drugs in development and is well-positioned to benefit from the growing demand for rare disease treatments. The company's financial profile is also strong, with a growing revenue stream and a low level of debt.
##
Analyst Recommendations
Analysts are bullish on Amicus Therapeutics. The consensus analyst rating is "buy." The average analyst price target is $17.27, which represents a potential upside of 44% from the current stock price.
